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Abstract 
 
Objectives. We aimed to determine the geographical variation in the proportion of non-small cell lung 
cancer (NSCLC) patients undergoing curative treatment and assess the relationship between treatment 
access rates and survival outcomes. 
Methods. We extracted cancer registration data on 144,357 lung cancer (excluding small cell tumours) 
patients diagnosed between 2009 and 2013. Surgical and radiotherapy treatment intensity quintiles were 
based on patients’ Clinical Commissioning Group (CCG) of residence. We used logistic regression to 
assess the effect of travel time and case-mix on treatment use and Cox regression to analyse survival in 
relation to treatment intensity. 
Results. There was wide variation in the use of curative treatment across CCGs, with the proportion 
undergoing surgery ranging from 8.9% to 20.2%, and 0.4% to 16.4% for radical radiotherapy. The odds 
of undergoing surgery decreased with socioeconomic deprivation (OR 0.91, 95% CI 0.85-0.97), whereas 
the opposite was observed for radiotherapy (OR1.16, 95% CI 1.08-1.25). There was an overall effect of 
travel time to thoracic surgery centre on the odds of undergoing surgery (OR 0.81, 95% CI 0.76-0.87 for 
travel time >55 min vs ≤15 min) which was amplified by the effect of deprivation. No clear association 
was observed for radiotherapy. Higher mortality rates were observed for the lower resection and 
radiotherapy quintiles (HR 1.08, 95% CI 1.04-1.12 and HR 1.06, 95% CI 1.02-1.10 for lowest vs. highest 
resection and radiotherapy quintile).  
Conclusion. There was wide geographical variation in the use of curative treatment and a higher 
frequency of treatment was associated with better survival.   
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1 Introduction 
Lung cancer is one of the three most common cancers in England with 36,637 newly diagnosed cases in 
2015 [ONS, 2017]. It is also the commonest cause of death from cancer with 30,520 deaths annually, 
representing 21% of all cancer deaths [ONS, 2017]. Although survival rates for lung cancer have been 
improving in England in recent years [1], they remain poor compared with many other cancers. In 
addition, survival rates in England are worse than those reported from a number of other countries with 
equivalent expenditure on healthcare [2, 3]. 
Almost 90% of all lung cancers diagnosed in England have non-small cell histology or are diagnosed on 
clinical grounds without tissue confirmation [4]. Fit, early stage non-small cell lung cancer (NSCLC) 
patients can be offered potentially curative treatment, either with surgical resection or radiotherapy, often 
combined with adjuvant chemotherapy. Wide variation in usage of surgical resection for NSCLC patients 
across England and a clear association between resection rate and survival has previously been 
demonstrated [5]. Such variation has also been demonstrated in other European countries [6, 7]. This 
may in part be attributable to patient and disease-related factors with performance status, comorbidity, 
age (with associated increasing frailty and patient choice) and disease stage all justifiably impacting 
upon the clinical decision-making process [8-10]. Differing interpretation of the clinical evidence 
supporting cancer treatment decisions may, however, result in varying practice [11] and previous small-
scale studies have demonstrated wide variation in Multi-Disciplinary Team (MDT) recommendations for 
identical presentations [12].  As such, variation in quality and access to stage specific treatments may, in 
part, underpin the relatively poor outcomes seen for NSCLC in the UK [3]. Analyses which focus upon 
surgery alone will, however, have a limited scope in a population often unfit for such an approach. In this 
often co-morbid population of NSCLC patients, radical radiotherapy is frequently more appropriate. 
Moreover, where surgical resection is not possible, radical radiotherapy can offer potential cure. As such, 
in order to assess effectiveness of curative treatment for NSCLC at the population level both treatment 
modalities should be considered. A priori, one could hypothesize that CCGs with high surgical resection 
rates would have low radical radiotherapy rates and vice versa, due to case-mix factors or historical local 
treatment preferences favouring one treatment over the other. Alternatively, one could hypothesize that 
CCGs that had high surgical resection rates also had high radical radiotherapy rates owing to a general 
appetite for curative treatment. 
This study aimed to determine the proportion of NSCLC patients in England undergoing potentially 
curative treatment and its geographical variation. We aimed to assess the impact of patient and tumour 
characteristics, and distance to nearest treatment centre on treatment rates and determine the 
relationship between rates of access to curative treatment and population level survival outcomes. 
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2 Methods 
2.1 Study population 
Data on 168,634 lung cancers (International Classification of Diseases [version 10] (ICD10) codes C33 
to C34) diagnosed in England between 1 April 2009 and 31 December 2013 were extracted from the 
National Cancer Registration Dataset [AV2013], held by the National Cancer Registration and Analysis 
Service at Public Health England. We excluded 18,492 cancers with small cell histology (ICD-O-2 
classification morphology codes 8041-8045), 3,865 cancers identified from death certificates only (DCO), 
and 113 cases without a recorded National Health Service (NHS) number. Only the first lung cancer 
recorded for each patient was included, which affected 1,689 patients with multiple primary lung cancers. 
The analyses focussed on adult lung cancer patients only, and excluded 43 patients under the age of 15 
and over 100. Finally, we excluded 75 patients with unknown vital status. The final data set thus included 
144,357 adult NSCLC patients, of whom 68% had a histological and/or cytological confirmation. 
2.2 Patient and tumour characteristics 
Information on patient demographics and tumour characteristics (including stage, anatomical topography 
and morphology) were extracted from the core cancer registration data. Information on death was 
obtained from the Office for National Statistics (ONS).  
Socioeconomic deprivation (SED) is based on the income domain of the Indices of Deprivation (version 
2015) [13] . Lower Super Output Areas (LSOAs, geographic areas of a consistent size that cover a 
population of approximately 1,500 persons) were grouped into five SED quintiles, each containing 20% 
of the population of England. The least deprived quintile was labelled 1 and the most deprived 5. 
Patients were assigned to an SED quintile based on their postcode of residence at the time of diagnosis. 
Performance status at diagnosis was available through patient level linkage with the National Lung 
Cancer Audit data [14].  
Comorbidity information was obtained from linked in-patient Hospital Episode Statistics (HES 2015) 
records [15].  Diagnoses (excluding cancer, for which information was retrieved from cancer registration 
records) from hospital admissions 27 months to 3 months prior to the lung cancer diagnosis were used 
to calculate the weighted Charlson comorbidity scores (CCS) [16]. The resulting scores were grouped 
into four categories of increasing severity (CCS 0, 1, 2, 3+). A small proportion of patients (0.9%) did not 
have a linked HES record and were assumed to have a CCS of 0. 
2.3 Treatment 
Information on surgical resection was retrieved from linked in-patient and day-case HES records. The 
cancer registration records were linked to HES records using a matching algorithm based on patient’s 
NHS number, date of birth, sex and postcode at diagnosis.  Less than 1% of records did not have a 
linked inpatient HES record and for these patients we assumed that they did not have any comorbid 
conditions. Surgical procedures recorded in the HES dataset are coded using  the Office of Population, 
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Censuses and Surveys Classification of Surgical Operations and Procedures (4th revision, OPCS-4) 
[17]. Types of surgical resections were included as previously defined [18]: lobectomy or bilobectomy 
(68%), partial lobectomy or wedge resection (16%), pneumonectomy (12%), sleeve resection (1%), and 
other less common procedures (other or unspecified excisions of (or lesions of) trachea, carina, lung, 
and chest wall, 4%). Surgical procedures from one month before to six months after the date of 
diagnosis were included. If patients had more than one recorded surgical procedure, the most extensive 
procedure was used in the analysis. 
Information on radiotherapy treatments was retrieved from the linked summary records in the national 
Radiotherapy Dataset (RTDS). The RTDS contains information on all episodes of radiotherapy delivered, 
but does not consistently capture the treatment intent, whether it be radical, adjuvant or palliative. In 
addition, disease coding varies between centres, for example, total attendances are captured in some 
centres rather than intended fractionation patterns, and radiation dose is not always recorded. We 
considered all episodes starting within six months from date of diagnosis for which a treatment site code 
for lung cancer (ICD 10 C33-C34) or unspecified respiratory tract cancer (C78, C80, D38, D02) was 
recorded in the RTDS. When information on the total radiation dose used was missing, the radiotherapy 
treatment intent was derived using criteria based on clinical guidelines. Thus, radical treatment was 
defined as: patients with at least one radiotherapy treatment summary record with either 15 or more 
attendances (with or without recorded dose); 3, 5 or 8 attendances with a dose higher than 50Gy 
(stereotactic ablative radiotherapy, SABR); or 3, 5 or 8 attendances without a dose but with stage I or II 
(reflecting TNM stage I through IIA (N0)) treated at a radiotherapy centre known to have performed 
SABR during the study period. The identification of SABR treatment was validated within two treating 
centres. In addition, patients with two radiotherapy episodes delivered to the chest within 2 weeks of 
each other and which together summed up to more than 15 attendances were classified as having had 
radical radiotherapy treatment. Lung cancer patients without a linked RTDS record were deemed to have 
received no radiotherapy treatment. If a patient underwent surgical resection and adjuvant radiotherapy, 
this was considered as primary surgical treatment in the analyses. 
To study geographical variation in treatment activity, we calculated the proportion of patients undergoing 
potentially curative treatment (surgical resection or radical radiotherapy) in each of the 211 Clinical 
Commissioning Groups (CCG). Because the two treatment modalities pertain to distinct groups of lung 
cancer patients, separate treatment intensity quintiles were created for surgical resection and radical 
radiotherapy, where Q1 is the quintile with the lowest and Q5 is the quintile with the highest treatment 
intensity. Patients were allocated to one of these quintiles based on their residential postcode at 
diagnosis linked to a CCG. 
Travel time was calculated for all patients from their residential postcode at the time of diagnosis to their 
nearest treatment centre, using the ArcGIS Spatial Analyst module [19]. Given that thoracic surgical 
centres and radiotherapy treatment centres are not always co-located, distance to each of these was 
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assessed separately. Because the variation in travel time to nearest surgical treatment centre was 
greater than that to radiotherapy centre, we categorised them separately as 0-15, 16-25, 26-35, 36-55, 
>55 minutes for nearest thoracic surgical centre and 0-10, 11-20, 21-30, 31-40, >40 minutes for nearest 
radiotherapy treatment centre. We assumed that each patient was treated at the nearest facility and 
used the ArcGIS to calculate the shortest travel distance to it. It is recognised that in some cases this 
would not be the treating centre, however, identifying the geographical extent of each treating centre’s 
catchment was not possible due to the lack of fixed health administrative boundaries, and thus nearest 
centre was used. Inaccurate or obsolete residential postcodes gave rise to missing travel times (0.5%). 
2.4 Data analysis 
The distribution of the patient characteristics (age, sex, SED, performance status, comorbidity) and 
tumour characteristics (stage, topography and morphology) were tabulated among all NSCLC patients 
and among patients undergoing surgical resection or radical radiotherapy. We used the Mantel-Haenszel 
test with 1 degree of freedom to assess the differences in case-mix by type of curative treatment, with 
the exception of age for which a Kruskal-Wallis rank test with 2 degrees of freedom was used. 
The proportions of patients undergoing potentially curative treatment, radical radiotherapy and surgical 
resection by CCG were plotted. To assess the relationship between the two curative treatment 
modalities at CCG level, a scatterplot depicting the proportion of NSCLC patients undergoing either 
radical radiotherapy or surgical resection by CCG was created. 
We used univariable and multivariable logistic regression to assess the association of distance to 
nearest treatment centre, patient and tumour characteristics with surgical resection and radical 
radiotherapy. We computed χ² values and p-values for trend and heterogeneity, where appropriate. To 
assess the combined effect of travel time and socioeconomic deprivation on the likelihood of receiving 
treatment the odds ratios for undergoing surgical resection or receiving radical radiotherapy were 
calculated relative to the least deprived quintile group living closest to a thoracic centre or a radiotherapy 
centre, respectively. 
Cox proportional hazards regression analyses were used to assess the association between CCG 
treatment intensity quintiles of surgical resection and radical radiotherapy and survival. For patients not 
undergoing curative treatment survival time was calculated from the date of diagnosis to death or 
censoring date. In order to avoid immortal time bias, for patients undergoing treatment survival time was 
calculated from the date of surgery or the starting date of radical radiotherapy. All patients were followed 
up until the date of death or censored on 31/12/2016. Multivariable models included CCG treatment 
intensity (surgical resection or radical radiotherapy) quintile with adjustment for age, sex, SED, 
performance status, comorbidity and disease stage. In addition to standard Cox regression models, we 
ran shared-frailty Cox models with CCG as a random effect to account for potential unobserved variation 
in survival related to living in distinct geographical areas. We found a significant frailty effect for all 
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models considered and therefore the results from the shared-frailty Cox models are reported here. We 
computed χ² values and p-values for trend and heterogeneity, where appropriate. 
To account for missing data, we also performed analyses based on imputed data. We used multiple 
imputation by chained equations to impute the missing data for stage and performance status. Twenty 
imputed datasets were created. We imputed the missing values for stage and performance status 
treatment using a model that included travel time, diagnosis year, age, sex, socio-economic deprivation, 
comorbidity, morphology, topography and survival time without interaction terms. 
All statistical analyses were carried out using Stata version 13.1 (StataCorp, Texas, USA). 
 
3 Results 
Table 1 shows the patient and tumour characteristics of 144,357 NSCLC patients. The median age was 
73 years (IQR 65-80), and the majority of patients were male (55.4%). Since we included patients from 1 
April 2009 to the end of 2013, there were relatively fewer patients diagnosed in 2009 included in this 
study compared to the other years (15.2% in 2009, compared to 20.6, 21.1, 21.7, and 21.3% of patients 
diagnosed in 2010-2013). There was a clear gradient of NSCLC patients predominantly living in areas 
with higher socioeconomic deprivation (26.0% in the most deprived versus 14.0% in the least deprived 
socioeconomic deprivation quintile). Performance status was unknown for 31.7% of patients, 33.5% of 
patients did not have a stage recorded, 26.7% had an unspecified topography and 32.0% did not have a 
histological confirmation.  
Of all NSCLC patients, 20.6% underwent potentially curative treatment: 14.0% underwent surgical 
resection and 6.6% underwent radical radiotherapy. The proportions of patients undergoing surgical 
resection increased from 12.2% in 2009 to 15.5% in 2013 and radical radiotherapy from 5.5% to 7.8% 
during the same period. Both surgical resection and radical radiotherapy offer potential cure to NSCLC 
patients, but patients undergoing either treatment modality differ. Whereas patients with stage I and II 
may be candidates for surgical resection, radical radiotherapy or chemoradiotherapy is usually the 
primary treatment modality for potentially curable stage III NSCLC. Patients who underwent surgical 
resection were younger (p=0.0001), more often female (p<0.0001), were more likely to live in the least 
socioeconomically deprived areas (p=0.0005), had better performance status (p<0.0001) and lower 
Charlson comorbidity scores (p=0.0237) than those who underwent radical radiotherapy. 
To assess the effect of travel time to treatment centre and case-mix on the odds of undergoing curative 
treatment, univariable and multivariable logistic regression analyses were performed (Table 2). There 
was a stark drop off in the odds of undergoing surgical resection associated with age over 75 (adjusted 
OR 0.76, 0.39 and 0.12 for ages 75-79, 80-85 and 85+, respectively, p-trend <0.0001). There was a less 
pronounced but significant trend of reduced odds of undergoing radical radiotherapy with age with the 
highest age group (85+) being almost half as likely compared to those aged <55 years of age (adjusted 
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OR 0.53, 95% CI 0.47-0.61, p-trend <0.0001). Whereas female NSCLC patients were 16% more likely to 
undergo surgical resection compared to males, there was no association between sex and the odds of 
undergoing radical radiotherapy. Whereas there was no clear association between diagnosis year and 
surgical resection in the multivariable model, patients diagnosed more recently were more likely to 
undergo radical radiotherapy compared to 2009 (adjusted OR 1.41,  95% CI 1.29-1.53 for 2013 versus 
2009, p-trend <0.0001). Performance status was more strongly associated with the odds of undergoing 
surgical resection (adjusted OR 0.02, 95% CI 0.01-0.04 for highest vs lowest, p-trend <0.0001) than 
radical radiotherapy (adjusted OR 0.04, 95% CI 0.02-0.06 for highest vs lowest, p-trend <0.0001).  We 
observed an increased likelihood of undergoing surgical resection among patients with comorbidity 
scores 1 and 2 compared with patients without any recorded comorbidity, and patients with comorbidity 
were also more like to receive radical radiotherapy. Following multiple imputation, the odds ratio of 
undergoing surgery remained significant for the group of patients with comorbidity score 2, but no 
significant trend across comorbidity groups was detected. An attenuated but significant trend remained 
for radiotherapy.  The association of stage with surgical resection reflects a 35% reduced likelihood of 
patients with stage II disease undergoing surgical resection compared to patients with stage I disease 
(95% CI 0.61-0.70).  
The variation in travel time to nearest surgical treatment centre was greater than that to radiotherapy 
centre (travel time to thoracic centre: median=30 min, IQR [18-48], travel time to RT centre: median=24 
min, IQR [14-35]). Most thoracic surgery units and radiotherapy centres are located in big cities where 
levels of deprivation tend to be higher. The proportion of patients living in the most deprived areas was 
highest in the quintile with shortest travel time to a treatment centre (44% for thoracic surgery centres 
and 37% for radiotherapy centres) and lowest in the furthest quintile (13.8% for thoracic surgery and 
17.0% for radiotherapy centres). The odds ratios of undergoing surgical resection decreased with 
increasing travel time to a thoracic surgery centre (adjusted OR 0.81, 95% CI 0.76-0.87 for travel time 
>55 min vs ≤15 min) and there was a significant trend in the odds ratios over the five travel time quintiles 
(p-trend <0.0001). No clear association was observed for radical radiotherapy. Higher levels of 
socioeconomic deprivation were associated with lower odds of undergoing surgical resection (adjusted 
OR 0.91, 95% CI 0.85-0.97 for highest vs lowest, p-trend <0.0001), whereas the opposite was observed 
for radical radiotherapy (adjusted OR 1.16, 95% CI 1.08-1.25 for highest vs lowest, p-trend <0.0001). For 
receipt of surgical resection, the adverse effect of travel time increased with increasing levels of 
deprivation, with the highest magnitude of the travel time trend observed for the most deprived group 
(Table 3a). Patients living furthest away from the nearest thoracic surgery unit and resident in areas with 
the two highest levels of deprivation had the lowest odds of receiving surgery (adjusted OR 0.72, 95% CI 
0.60-0.88 and OR 0.73, 95% CI 0.59-0.91 for deprivation quintiles 4 and 5 respectively).  There was no 
clear pattern of variation in access to radical radiotherapy in relation to travel time and socioeconomic 
deprivation (Table 3b). For patients resident in the most deprived areas the odds of receiving radical 
radiotherapy were consistently higher although with little difference by travel time.   
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Figure 1 shows the significant variation in the use of potentially curative treatment by CCG. The 
proportion of NSCLC patients receiving curative treatment ranged from 11.8% to 31.7. The proportion 
undergoing surgical resection ranged from 8.9% to 20.2% (panel a) (England average 13.9%), whereas 
the proportion receiving radical radiotherapy ranged from 0.4% to 16.4% (panel b) (England average 
6.4%). We did not find evidence of either positive or inverse correlation between CCG based rates of 
surgical resection and rates of radical radiotherapy in the scatterplot (Pearson correlation coefficient ρ=-
0.03) (panel c). Given the variation in both treatment modalities, we focussed the subsequent survival 
analyses on CCG variation in intensity of surgical resection and radical radiotherapy separately. 
Results from the univariable and multivariable Cox shared-frailty models are shown in Table 4. 
Compared to patients living in areas with the highest surgical resection rates, higher mortality rates were 
observed for the lower surgical resection quintiles, and some attenuation was observed when adjusted 
for case-mix (HR 1.08, 95% CI 1.04-1.12 for lowest vs. highest resection quintile, p-trend 0.0001). A 
similar magnitude was observed for radical radiotherapy quintile (HR 1.06, 95% CI 1.02-1.10 for lowest 
vs. highest resection quintile, p-trend 0.0034). Among the treated patients only, the associations were 
reversed although not statistically significant, and trends not clear. 
A sensitivity analysis was performed by repeating logistic and Cox regression analyses with imputed 
data. With the exception of comorbidity (discussed above) the relationships between the independent 
variables and treatment, and between treatment intensity and mortality were not materially affected by 
the imputation performed (supplementary data). 
 
4 Discussion  
This study found wide geographical variation in access to potentially curative treatments of 12 to 32% of 
NSCLC patients receiving potentially curative treatment by CCG, and that this variation stemmed from 
variation in both surgical resection and radical radiotherapy rates that did not appear to be correlated. 
The variation in access to both treatment modalities affected survival of NSCLC patients in England. The 
surgical resection rate of 16% during the study period is in line with previously published results from the 
National Lung Cancer Audit [20]. Between 2004 and 2008 major surgical resection rates of 17.5-24% are 
reported in European studies [6, 7, 21]. Rates in England do not compare favourably, and despite 
improvements toward the end of the study period, overall resection rates remain low by international 
comparison. There is limited information regarding rates of radical radiotherapy internationally.  
In agreement with previously reported studies [22, 23] we found that increasing travel time to treating 
centre is significantly associated with lower rates of surgical treatment for lung cancer, but the 
association with radical radiotherapy treatment was less clear. Furthermore, we found that travel time to 
the nearest thoracic surgery unit exacerbated the effects of socioeconomic deprivation, with the patients 
living furthest away from the nearest thoracic surgery unit and resident in areas with the two highest 
levels of deprivation having significantly lower likelihood of undergoing surgical resection. Travel time did 
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not appear to alter the effects of socioeconomic deprivation on the likelihood of being treated with radical 
radiotherapy. Travel times to the nearest thoracic centre were greater than for nearest radiotherapy 
centre, but even when equivalent travel time intervals were analysed, the difference in association 
persisted (data not shown). An earlier study showed similar associations of a more pronounced 
association between travel time to nearest hospital and receipt of surgery than radiotherapy in the north 
of England [23, 24].    
Both patient and organisational reasons could be responsible for this. From a patient perspective, travel 
implications for radiotherapy could be expected to have a greater impact because of the need for 
repeated treatments, as opposed to a single hospitalisation for surgery. Travel time can also be a 
significant burden on carers, and an in-patient stay for surgery may constitute a bigger burden on carers 
if the distance is greater. Patient travel for treatment is frequently provided free of charge for those 
undergoing radiotherapy whilst the same is not true for carers travelling to visit hospital. Our finding 
provides valuable information to commissioners and clinicians about a need for increased vigilance to 
the risk of reduced access to treatment in the presence of longer travel times, particularly in the 
presence of socio-economic deprivation [25]. Patient hotels in treatment centres are already 
recommended and targeting their increased use to this patient group could be considered [26, 27].  
From a health care organisational perspective, the distance to thoracic centre may be related to a 
difference in the likelihood of being considered for surgical resection based on the hospital where the 
patient was first seen. Evidence from the National Lung Cancer Audit has shown that patients with 
NSCLC first seen in a thoracic surgical centre are more likely to have surgery [28]. Variation in the use of 
appropriate staging investigations, local availability of complex techniques (such as SABR) and intra-
disciplinary team working may contribute to the observed difference in access to radical radiotherapy. 
These factors have not been accounted for here, and further work is required to investigate whether, and 
what institutional differences account for this variation in order to identify possible strategies to improve 
treatment rates and outcomes. 
Our findings with regard to access to potentially curative treatment in relation to other patient 
demographics and tumour characteristics are in line with previous reports with regard to increasing age, 
male sex, poor performance status and advanced stage all associated with lower odds of receiving 
potentially curative treatment. We observed an increase in the likelihood of undergoing potentially 
curative treatment for patients with any comorbidity compared with those with no recorded comorbidity. It 
is plausible that some patients with comorbid conditions requiring inpatient care were under closer 
clinical surveillance or had been in contact with the health care system and therefore their lung cancer 
was discovered at an early stage, making them more likely to receive curative treatment. However, it is 
of interest, that the associations were much attenuated when we applied multiple imputation to account 
for the missing data for stage and performance status, raising the possibility that the association may 
result from residual confounding.  
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It is of interest that increasing level of socioeconomic deprivation was associated with higher access to 
radiotherapy, which is in contrast to a reverse association between socioeconomic deprivation and 
surgical resection. The higher rates of radical radiotherapy in patients living in the more deprived areas 
may well simply be the inverse of the surgical findings, with more deprived patients more likely to be 
offered or choose radical radiotherapy over surgery. As noted above SED also further exacerbated the 
reduction in access to surgery associated with longer travel times.  
The differences in access to treatment have a clear effect on the outcomes for lung cancer patients, both 
for surgical resection and for radical radiotherapy. Some attenuation by case-mix was found. When the 
survival analyses were restricted to the treated patients only, among the surgically resected patients we 
see diminishing returns of increasing resection rates, possibly indicating that the high treatment areas 
include more complicated patients. Among the patients treated with radical radiotherapy no such effect 
was found, possibly indicating that the rate of radical radiotherapy reported here is well below its optimal 
level. 
This study is strengthened by assessing rates of treatment across the whole of England acknowledging 
both surgical and radiotherapy treatments delivered with a view to cure. It does, however, have a 
number of limitations. The surgical resections identified from the inpatient HES data using the OPCS-4 
codes provide a robust measure of surgical treatment intensity in England. The radiotherapy data as 
available from the RTDS proved more difficult, as only summarised numbers of attendances were 
available and not fractions, and only 73% of records had a valid dose recorded. Using our algorithm, 
taking into account time between summarised episodes of radiotherapy attendances, SABR identified by 
proxy using stage and centre information, the proportion of patients identified as receiving radical 
radiotherapy increased from 6% to 7.15%. A validation study comparing patients as identified from the 
RTDS as having undergone radical radiotherapy against trust records from two radiotherapy centres 
revealed a 95% concordance. Although this shows that we may have missed a small proportion of 
patients receiving radical radiotherapy, it is unlikely that this is differential misclassification. As such, we 
feel that both the geographical variation observed and the impact on survival is real. 
Another limitation of this study is that we did not have information on use of chemotherapy, and therefore 
cannot assess the impact in difference between radical radiotherapy alone versus chemoradiotherapy. 
Depending on whether use of chemoradiotherapy varies in the same way that radical radiotherapy does, 
we may be underestimating the impact this variation has on survival. Furthermore, data on stage, 
performance status and morphology was frequently missing and varied between the group of patients 
receiving treatment and those not receiving treatment.  To assess the impact of missing data sensitivity 
analysis was performed by repeating regression analyses following multiple imputation. With the 
exception of comorbidity (discussed above) the relationships between the independent variables and the 
treatment likelihood, and between treatment intensity and mortality were not materially affected by the 
imputation performed. 
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Finally, CCGs were used as the geographical unit for comparison. These were created following the 
Health and Social Care Act in 2012, and replaced Primary Care Trusts (PCTs) on 1 April 2013, and as 
such were not present for the time period covered by the data presented here. We are therefore limited 
to interpret our findings in terms of geographically based treatment intensity quintiles rather than in terms 
of commissioning structures. Moreover, potentially curative lung cancer treatments are delivered in 
tertiary referral centres with patients diagnosed in most hospitals in England. Many of these have MDTs 
and these should all have surgical and clinical oncology representation (in line with National Institute for 
Health and Care Excellence Clinical Guidelines) [29].  Ideally case-mix adjusted rates of potentially 
curative treatment, with appropriate comparisons, would be delivered at MDT level in order to guide 
service improvement where necessary. The data used in this study do not directly support the necessary 
analysis due to the complex referral pathways involved and one to many relationship between CCGs and 
MDTs. 
This study demonstrates significant geographical variation in the use of potentially curative treatment for 
NSCLC, and that there is no correlation between surgical resection and radical radiotherapy rates. In 
addition, we found that increasing both surgical resection and radical radiotherapy rates are associated 
with lower population mortality among all NSCLC patients. Whilst influenced by case-mix this association 
persists after adjustment, suggesting it may be driven by other factors not studied here, for example 
institutional and environmental factors or unmeasured confounding variables at patient level. Exploring 
these additional factors will play an important part in understanding the observed variation in curative 
treatment rates for NSCLC patients across the English NHS and delivering improvements in both access 
and outcomes. 
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Table 1 Patient and tumour characteristics by curative treatment type (surgical resection, radical radiotherapy, and no treatment) 
  Total Surgical treatment Radical RT treatment No treatment Mantel-Haenszel 
  n col % n col % n col % n col % χ2 (1) df,
  144,357   20,208 14.0 9,512 6.6 114,637 79.4 p-value
Age 
median 73 69 71 74 5373.362
IQR [65 80] [62 75] [64 77] [66 82] 0.0001*
Sex 
Male 79,924 55.4 10,514 52.0 5,578 58.6 63,832 55.7 59.5366
Female 64,433 44.6 9,694 48.0 3,934 41.4 50,805 44.3 <.0001
Diagnosis year
2009 21,935 15.2 2,675 13.2 1,202 12.6 18,058 15.8
2010 29,743 20.6 3,801 18.8 1,753 18.4 24,189 21.1
2011 30,504 21.1 4,193 20.8 1,929 20.3 24,382 21.3
2012 31,389 21.7 4,781 23.7 2,239 23.5 24,369 21.3 305.9995
2013 30,786 21.3 4,758 23.6 2,389 25.1 23,639 20.6 <.0001
Socioeconomic deprivation quintile 
1 (most affluent) 20,201 14.0 3,077 15.2 1,213 12.8 15,911 13.9
2 25,986 18.0 3,858 19.1 1,553 16.3 20,575 18.0
3 28,810 20.0 3,921 19.4 1,831 19.3 23,058 20.1
4 31,822 22.0 4,222 20.9 2,091 22.0 25,509 22.3 12.2393
5 (most deprived) 37,538 26.0 5,130 25.4 2,824 29.7 29,584 25.8 0.0005
Performance status score 
0 19,946 13.8 7,294 36.1 2,296 24.1 10,356 9.0
1 32,788 22.7 6,221 30.8 3,782 39.8 22,785 19.9
2 20,188 14.0 997 4.9 1,544 16.2 17,647 15.4
3 19,091 13.2 126 0.6 328 3.5 18,637 16.3
4 6,592 4.6 12 0.1 16 0.2 6,564 5.7 779.136
Not known 45,752 31.7 5,558 27.5 1,546 16.3 38,648 33.7 <.0001
Comorbidity score
0 105,632 73.2 14,852 73.5 6,809 71.6 83,971 73.3
1 19,941 13.8 2,791 13.8 1,436 15.1 15,714 13.7
2 10,396 7.2 1,619 8.0 706 7.4 8,071 7.0 5.1198
3+ 8,388 5.8 946 4.7 561 5.9 6,881 6.0 0.0237
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Stage 
I 13,963 9.7 7,676 38.0 1,857 19.5 4,430 3.9
II 7,848 5.4 3,692 18.3 970 10.2 3,186 2.8
III 20,810 14.4 2,134 10.6 3,342 35.1 15,334 13.4
IV 53,363 37.0 759 3.8 723 7.6 51,881 45.3 449.9742
Not known 48,373 33.5 5,947 29.4 2,620 27.5 39,806 34.7 <.0001
Topography
Trachea 139 0.1 18 0.1 30 0.3 91 0.1
Main bronchus 6,919 4.8 222 1.1 449 4.7 6,248 5.5
Upper lobe 61,035 42.3 11,389 56.4 5,383 56.6 44,263 38.6
Middle lobe 4,826 3.3 955 4.7 323 3.4 3,548 3.1
Lower lobe 32,327 22.4 6,506 32.2 2,002 21.1 23,819 20.8
Overlapping 
lesion 637 0.4 196 1.0 22 0.2 419 0.4 4201.8295
Not specified 38,474 26.7 922 4.6 1,303 13.7 36,249 31.6 <.0001
Morphology
Adenocarcinoma 43,340 30.0 10,172 50.3 2,398 25.2 30,770 26.8
Carcinoid 3,000 2.1 1,407 7.0 80 0.8 1,513 1.3
Large cell 1,388 1.0 373 1.9 75 0.8 940 0.8
Non small cell 19,197 13.3 714 3.5 1,451 15.3 17,032 14.9
Other specified 336 0.2 136 0.7 9 0.1 191 0.2
Squamous 32,222 22.3 6,908 34.2 4,161 43.7 21,153 18.5 6107.4635
Unspecified 44,874 31.1 498 2.5 1,338 14.1 43,038 37.5 <.0001
* Kruskal-Wallis equality-of-populations rank test   
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Table 2 Odds ratios (95% CI) of receiving treatment from univariable and multivariable logistic regression models by (a) surgical resection and 
(b) radical radiotherapy, including travel time and case-mix. 
a) 
Total 
number of 
patients  
Patients 
undergoing 
surgical resection
Model 1: unadjusted Model 2: multivariable* 
  N N row % OR 95% CI OR 95% CI 
Travel time to thoracic centre 
<=15min 29,370 4,376 14.9 1 1
15-25min 29,375 4,299 14.6 0.98 0.94 1.02 1.06 1.00 1.14
25-35min 25,023 3,547 14.2 0.94 0.90 0.99 0.97 0.90 1.03
35-55 min 32,900 4,422 13.4 0.89 0.85 0.93 0.88 0.82 0.93
>55 min 26,939 3,486 12.9 0.85 0.81 0.89 0.81 0.76 0.87
NK 750 78 10.4 0.66 0.52 0.84 0.67 0.49 0.91
2   62.29   60.85
p-trend   0.0000   0.0000
Age 
<55 years 8,650 1,816 21.0 1 1
55-59 years 8,874 1,674 18.9 0.87 0.81 0.94 0.96 0.87 1.06
60-64 years 15,767 3,105 19.7 0.92 0.86 0.98 1.01 0.92 1.10
65-69 years 21,643 4,227 19.5 0.91 0.86 0.97 1.03 0.94 1.12
70-74 years 24,279 4,201 17.3 0.79 0.74 0.84 0.94 0.87 1.03
75-79 years 24,608 3,396 13.8 0.60 0.57 0.64 0.76 0.70 0.83
80-84 years 21,582 1,479 6.9 0.28 0.26 0.30 0.39 0.36 0.44
85+ years 18,954 310 1.6 0.06 0.06 0.07 0.12 0.11 0.14
2   3894.79   862.20
p-trend   0.0000   0.0000
Sex 
Male 79,924 10,514 13.2 1 1
Female 64,433 9,694 15.0 1.17 1.13 1.20 1.16 1.11 1.21
2   105.72   46.42
p-hetrogeneity   0.0000   0.0000
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Diagnosis year
2009 21,935 2,675 12.2 1 1
2010 29,743 3,801 12.8 1.05 1.00 1.11 1.07 1.00 1.15
2011 30,504 4,193 13.7 1.15 1.09 1.21 1.04 0.97 1.11
2012 31,389 4,781 15.2 1.29 1.23 1.36 1.04 0.96 1.12
2013 30,786 4,758 15.5 1.32 1.25 1.38 1.01 0.94 1.09
2   182.83   0.09
p-trend   0.0000   0.7613
Socioeconomic deprivation quintile 
1 (most affluent) 20,201 3,077 15.2 1 1
2 25,986 3,858 14.8 0.97 0.92 1.02 1.00 0.93 1.08
3 28,810 3,921 13.6 0.88 0.83 0.92 0.91 0.85 0.98
4 31,822 4,222 13.3 0.85 0.81 0.90 0.87 0.81 0.93
5 (most deprived) 37,538 5,130 13.7 0.88 0.84 0.92 0.91 0.85 0.97
2   43.16   17.40
p-trend   0.0000   0.0000
Performance status score 
0 19,946 7,294 36.6 1 1
1 32,788 6,221 19.0 0.41 0.39 0.42 0.45 0.43 0.48
2 20,188 997 4.9 0.09 0.08 0.10 0.13 0.12 0.14
3 19,091 126 0.7 0.01 0.01 0.01 0.03 0.03 0.04
4 6,592 12 0.2 0.00 0.00 0.01 0.02 0.01 0.04
Not known 45,752 5,558 12.1 0.24 0.23 0.25 0.50 0.47 0.53
2   9581.43   3442.79
p-trend   0.0000   0.0000
Comorbidity score
0 105,632 14,852 14.1 1 1
1 19,941 2,791 14.0 0.99 0.95 1.04 1.08 1.02 1.15
2 10,396 1,619 15.6 1.13 1.07 1.19 1.30 1.20 1.41
3+ 8,388 946 11.3 0.78 0.72 0.83 1.04 0.94 1.15
2   9.93   20.28
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p-trend   0.0016   0.0000
Stage 
I 13,963 7,676 55.0 1 1
II 7,848 3,692 47.0 0.73 0.69 0.77 0.65 0.61 0.70
III 20,810 2,134 10.3 0.09 0.09 0.10 0.06 0.06 0.06
IV 53,363 759 1.4 0.01 0.01 0.01 0.01 0.01 0.01
Not known 48,373 5,947 12.3 0.11 0.11 0.12 0.13 0.12 0.14
2   19405.31   12971.79
p-trend   0.0000   0.0000
Topography
C33 139 18 12.9 0.65 0.40 1.06 0.36 0.21 0.60
C340 6,919 222 3.2 0.14 0.13 0.17 0.21 0.18 0.25
C341 61,035 11,389 18.7 1 1
C342 4,826 955 19.8 1.08 1.00 1.16 0.97 0.87 1.07
C343 32,327 6,506 20.1 1.10 1.06 1.14 1.14 1.09 1.19
C348 637 196 30.8 1.94 1.64 2.30 2.38 1.86 3.04
C349 38,474 922 2.4 0.11 0.10 0.11 0.18 0.17 0.20
2   5213.49   2433.29
p-hetrogeneity   0.0000   0.0000
Morphology
Adenocarcinoma 43,340 10,172 23.5 1 1
Carcinoid 3,000 1,407 46.9 2.88 2.67 3.10 2.15 1.93 2.40
Large cell 1,388 373 26.9 1.20 1.06 1.35 1.12 0.95 1.33
Non small cell 19,197 714 3.7 0.13 0.12 0.14 0.14 0.12 0.15
Other specified 336 136 40.5 2.22 1.78 2.76 2.14 1.65 2.79
Squamous 32,222 6,908 21.4 0.89 0.86 0.92 0.70 0.67 0.73
Unspecified 44,874 498 1.1 0.04 0.03 0.04 0.05 0.04 0.05
2   8809.80   5455.07
p-hetrogeneity   0.0000   0.0000
* adjusted for: travel time to nearest thoracic centre, age, sex, diagnosis year, socioeconomic deprivation, performance status, comorbidity score, stage, 
topography and morphology 
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b) 
Total 
number of 
patients  
Patients 
undergoing 
radical 
radiotherapy
Model 1: unadjusted Model 2: multivariable* 
  N N row % OR 95% CI OR 95% CI 
Travel time to radiotherapy centre 
<=10min 21,043 1,458 5.0 1 1
10-20min 33,682 2,270 7.7 0.97 0.91 1.04 0.99 0.92 1.06
20-30min 36,724 2,381 9.5 0.93 0.87 1.00 0.97 0.90 1.04
30-40min 26,855 1,806 5.5 0.97 0.90 1.04 1.01 0.93 1.09
>40min 25,303 1,546 5.7 0.87 0.81 0.94 0.91 0.84 0.99
NK 750 51 6.8 0.98 0.73 1.31 0.97 0.72 1.32
2   10.55   3.61
p-trend   0.0012   0.0574
Age 
<55 years 8,650 651 7.5 1 1
55-59 years 8,874 717 8.1 1.08 0.97 1.21 0.94 0.84 1.06
60-64 years 15,767 1,260 8.0 1.07 0.97 1.18 0.91 0.82 1.01
65-69 years 21,643 1,695 7.8 1.04 0.95 1.15 0.88 0.79 0.97
70-74 years 24,279 1,805 7.4 0.99 0.90 1.08 0.84 0.76 0.93
75-79 years 24,608 1,644 6.7 0.88 0.80 0.97 0.82 0.74 0.91
80-84 years 21,582 1,188 5.5 0.72 0.65 0.79 0.79 0.71 0.88
85+ years 18,954 552 2.9 0.37 0.33 0.41 0.53 0.47 0.61
2   434.84   86.40
p-trend   0.0000   0.0000
Sex 
Male 79,924 5,578 7.0 1 1
Female 64,433 3,934 6.1 0.87 0.83 0.90 0.97 0.92 1.01
2   44.17   2.12
p-hetrogeneity   0.0000   0.1450
Diagnosis year
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2009 21,935 1,202 5.5 1 1
2010 29,743 1,753 5.9 1.08 1.00 1.17 1.14 1.05 1.23
2011 30,504 1,929 6.3 1.16 1.08 1.25 1.19 1.10 1.29
2012 31,389 2,239 7.1 1.32 1.23 1.42 1.28 1.18 1.40
2013 30,786 2,389 7.8 1.45 1.35 1.56 1.41 1.29 1.53
2   151.02   68.40
p-trend   0.0000   0.0000
Socioeconomic deprivation quintile 
1 (most affluent) 20,201 1,213 6.0 1 1
2 25,986 1,553 6.0 0.99 0.92 1.08 0.96 0.88 1.04
3 28,810 1,831 6.4 1.06 0.99 1.15 1.02 0.94 1.11
4 31,822 2,091 6.6 1.10 1.02 1.18 1.02 0.95 1.10
5 (most deprived) 37,538 2,824 7.5 1.27 1.19 1.37 1.16 1.08 1.25
2   69.57   26.02
p-trend   0.0000   0.0000
Performance status score 
0 19,946 2,296 11.5 1 1
1 32,788 3,782 11.5 1.00 0.95 1.06 1.11 1.05 1.18
2 20,188 1,544 7.6 0.64 0.59 0.68 0.84 0.78 0.90
3 19,091 328 1.7 0.13 0.12 0.15 0.22 0.19 0.25
4 6,592 16 0.2 0.02 0.01 0.03 0.04 0.02 0.06
Not known 45,752 1,546 3.4 0.27 0.25 0.29 0.40 0.37 0.43
2   2022.59   883.63
p-trend   0.0000   0.0000
Comorbidity score
0 105,632 6,809 6.4 1 1
1 19,941 1,436 7.2 1.13 1.06 1.19 1.17 1.10 1.24
2 10,396 706 6.8 1.06 0.98 1.15 1.12 1.03 1.22
3+ 8,388 561 6.7 1.04 0.95 1.14 1.25 1.14 1.38
2   5.42   34.59
p-trend   0.0199   0.0000
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Stage 
I 13,963 1,857 13.3 1 1
II 7,848 970 12.4 0.92 0.85 1.00 0.81 0.75 0.89
III 20,810 3,342 16.1 1.25 1.17 1.33 1.14 1.07 1.21
IV 53,363 723 1.4 0.09 0.08 0.10 0.11 0.10 0.12
Not known 48,373 2,620 5.4 0.37 0.35 0.40 0.59 0.55 0.63
2   3206.31   2122.87
p-trend   0.0000   0.0000
Topography
C33 139 30 21.6 2.85 1.90 4.27 3.05 1.99 4.67
C340 6,919 449 6.5 0.72 0.65 0.79 0.85 0.76 0.95
C341 61,035 5,383 8.8 0 1
C342 4,826 323 6.7 0.74 0.66 0.83 0.81 0.72 0.91
C343 32,327 2,002 6.2 0.68 0.65 0.72 0.70 0.66 0.74
C348 637 22 3.5 0.37 0.24 0.57 0.36 0.23 0.56
C349 38,474 1,303 3.4 0.36 0.34 0.39 0.66 0.62 0.71
2   1130.95   303.89
p-hetrogeneity   0.0000   0.0000
Morphology
Adenocarcinoma 43,340 2,398 5.5 0 1
Carcinoid 3,000 80 2.7 0.47 0.37 0.59 0.41 0.33 0.52
Large cell 1,388 75 5.4 0.98 0.77 1.24 0.84 0.66 1.06
Non small cell 19,197 1,451 7.6 1.40 1.30 1.49 1.77 1.64 1.90
Other specified 336 9 2.7 0.47 0.24 0.91 0.51 0.26 0.99
Squamous 32,222 4,161 12.9 2.53 2.40 2.67 2.01 1.90 2.13
Unspecified 44,874 1,338 3.0 0.52 0.49 0.56 1.02 0.95 1.11
2   2891.68   912.00
p-hetrogeneity   0.0000   0.0000
* adjusted for: travel time to nearest radiotherapy centre, age, sex, diagnosis year, socioeconomic deprivation, performance status, comorbidity score, 
stage, topography and morphology 
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Table 3 Odds ratios (95% CI) of receiving treatment by quintiles of travel time and socioeconomic deprivation from univariable and multivariable 
logistic regression models by (a) surgical resection and (b) radical radiotherapy 
a)     
  Socioeconomic deprivation
Travel time 1 least deprived 2 3 4 5 most deprived 
Unadjusted model   
Closest 1   1.02 (0.88 - 1.18) 0.86 (0.74 - 0.99) 0.94 (0.82 - 1.08) 0.94 (0.83 - 1.06)
2 1.00 (0.87 - 1.16) 1.02 (0.88 - 1.17) 0.97 (0.85 - 1.11) 0.85 (0.74 - 0.97) 0.86 (0.75 - 0.98)
3 1.04 (0.90 - 1.20) 0.92 (0.80 - 1.06) 0.89 (0.77 - 1.02) 0.82 (0.71 - 0.94) 0.82 (0.72 - 0.94)
4 0.91 (0.80 - 1.05) 0.91 (0.80 - 1.04) 0.79 (0.69 - 0.90) 0.80 (0.69 - 0.91) 0.76 (0.66 - 0.88)
Furthest 0.92 (0.80 - 1.07) 0.88 (0.77 - 1.01) 0.77 (0.68 - 0.89) 0.70 (0.61 - 0.81) 0.72 (0.61 - 0.83)
    
Fully adjusted model*   
Closest 1   0.99 (0.81 - 1.22) 0.88 (0.72 - 1.07) 1.01 (0.84 - 1.22) 1.06 (0.89 - 1.26)
2 1.05 (0.86 - 1.29) 1.18 (0.97 - 1.44) 1.16 (0.96 - 1.40) 0.98 (0.81 - 1.18) 1.08 (0.90 - 1.30)
3 1.11 (0.91 - 1.35) 1.02 (0.84 - 1.24) 0.99 (0.82 - 1.21) 0.95 (0.78 - 1.15) 0.92 (0.76 - 1.11)
4 0.99 (0.82 - 1.20) 1.01 (0.83 - 1.21) 0.85 (0.70 - 1.03) 0.85 (0.70 - 1.02) 0.80 (0.66 - 0.97)
Furthest 0.95 (0.78 - 1.16) 0.93 (0.77 - 1.12) 0.84 (0.70 - 1.01) 0.72 (0.60 - 0.88) 0.73 (0.59 - 0.91)
    
b)   
  Socioeconomic deprivation
Travel time 1 least deprived 2 3 4 5 most deprived 
Unadjusted model   
Closest 1   1.28 (1.00 - 1.63) 1.25 (0.99 - 1.57) 1.23 (0.99 - 1.54) 1.50 (1.22 - 1.85)
2 0.97 (0.77 - 1.23) 1.14 (0.92 - 1.42) 1.29 (1.04 - 1.60) 1.28 (1.04 - 1.58) 1.47 (1.20 - 1.79)
3 1.28 (1.03 - 1.59) 1.12 (0.90 - 1.38) 1.12 (0.90 - 1.38) 1.19 (0.96 - 1.46) 1.39 (1.14 - 1.71)
4 1.09 (0.87 - 1.37) 1.14 (0.92 - 1.43) 1.25 (1.00 - 1.55) 1.33 (1.07 - 1.64) 1.52 (1.23 - 1.87)
Furthest 1.19 (0.95 - 1.51) 1.02 (0.82 - 1.27) 1.14 (0.92 - 1.42) 1.20 (0.96 - 1.49) 1.24 (0.99 - 1.56)
    
Fully adjusted model*   
Closest 1   1.29 (1.00 - 1.66) 1.20 (0.94 - 1.52) 1.12 (0.89 - 1.41) 1.39 (1.12 - 1.73)
2 0.99 (0.78 - 1.26) 1.09 (0.87 - 1.37) 1.27 (1.02 - 1.59) 1.20 (0.97 - 1.50) 1.35 (1.09 - 1.67)
3 1.34 (1.07 - 1.68) 1.08 (0.87 - 1.36) 1.06 (0.85 - 1.33) 1.12 (0.90 - 1.39) 1.29 (1.04 - 1.60)
4 1.07 (0.84 - 1.36) 1.09 (0.86 - 1.37) 1.20 (0.96 - 1.51) 1.24 (0.99 - 1.55) 1.44 (1.15 - 1.79)
Furthest 1.15 (0.90 - 1.46) 0.99 (0.78 - 1.24) 1.11 (0.88 - 1.39) 1.14 (0.91 - 1.42) 1.13 (0.89 - 1.42)
* adjusted for: age, sex, diagnosis year, performance status, comorbidity score, stage, topography and morphology 
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Table 4 Mortality hazard ratio (95% CI) for surgical resection and radical radiotherapy treatment intensity quintiles among (a) all NSCLC 
patients and (b) treated patients only 
a) Surgical resection Radical radiotherapy b) Surgical resection Radical radiotherapy 
HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Model 1: adjusted for age and sex Model 1: adjusted for age and sex
Q1 - lowest 1.12 1.09 1.15 1.08 1.05 1.12 Q1 - lowest 0.93 0.86 1.01 0.95 0.86 1.05 
Q2 1.05 1.02 1.09 1.05 1.01 1.08 Q2 0.90 0.83 0.98 1.03 0.94 1.13 
Q3 1.04 1.01 1.08 1.06 1.03 1.09 Q3 0.96 0.89 1.04 0.99 0.91 1.08 
Q4 1.01 0.98 1.04 1.02 0.99 1.05 Q4 0.92 0.85 0.99 0.95 0.87 1.03 
Q5 - highest 1     1 Q5 - highest 1 1   
2   61.47 27.80 2 3.50 0.04 
p-trend   0.0000 0.0000 p-trend 0.0614 0.8472 
Model 2: fully adjusted* Model 2: fully adjusted*
Q1 - lowest 1.08 1.04 1.12 1.06 1.02 1.10 Q1 - lowest 0.94 0.87 1.02 0.93 0.85 1.03 
Q2 1.02 0.98 1.06 1.08 1.03 1.13 Q2 0.90 0.84 0.97 1.05 0.96 1.15 
Q3 1.04 1.00 1.08 1.08 1.03 1.12 Q3 0.97 0.90 1.04 1.00 0.92 1.08 
Q4 0.99 0.95 1.03 1.05 1.00 1.09 Q4 0.90 0.84 0.97 0.94 0.87 1.02 
Q5 - highest 1     1 Q5 - highest 1 1   
2   16.1 8.57 2 2.39 0.06 
p-trend   0.0001 0.0034 p-trend 0.1223 0.8104 
* age, sex, diagnosis year, socio-economic deprivation, performance status, comorbidity, 
stage, topography, morphology 
* age, sex, diagnosis year, socio-economic deprivation, performance status, comorbidity, 
stage, topography, morphology 
 
 
 
Figure 1 The proportions of patients treated with a) surgical resection b) radical radiotherapy by CCG as well as c) the scatter plot of the 
proportion receiving resection by radiotherapy for each CCG  
Supplementary Table A: Odds ratios (95% CI) of receiving treatment from multivariable logistic regression models 
with imputed data by (a) surgical resection and (b) radical radiotherapy 
            
a) Multivariable model*   b) Multivariable model* 
  OR 95% CI   OR 95% CI 
Travel time to thoracic centre Travel time to radiotherapy centre
<=15min 1   <=10min 1 
15-25min 1.04 0.97 1.12 10-20min 0.99 0.92 1.06
25-35min 0.96 0.89 1.04 20-30min 0.97 0.90 1.04
35-55 min 0.86 0.80 0.93 30-40min 1.00 0.93 1.08
>55 min 0.83 0.76 0.89 >40min 0.91 0.84 0.98
NK 0.60 0.43 0.85 NK 0.98 0.72 1.34
2 13.66   2 0.08 
p-trend 0.0002   p-trend 0.7815 
Age Age
<55 years 1   <55 years 1 
55-59 years 0.99 0.88 1.12 55-59 years 0.97 0.86 1.09
60-64 years 1.00 0.90 1.12 60-64 years 0.92 0.83 1.03
65-69 years 1.01 0.91 1.12 65-69 years 0.88 0.80 0.98
70-74 years 0.94 0.84 1.04 70-74 years 0.86 0.77 0.95
75-79 years 0.75 0.67 0.83 75-79 years 0.83 0.75 0.92
80-84 years 0.39 0.34 0.43 80-84 years 0.81 0.73 0.91
85+ years 0.13 0.11 0.15 85+ years 0.56 0.49 0.63
2 673.13   2 73.51 
p-trend <0.0001   p-trend <0.0001 
Sex Sex
Male  1   Male  1 
Female 1.08 1.03 1.14 Female 0.95 0.91 1.00
2 10.07   2 4.06 
p-heterogeneity 0.0015   p-heterogeneity 0.0439 
 Diagnosis year
2009 1   2009 1 
2010 1.16 1.06 1.28 2010 1.15 1.06 1.25
2011 1.15 1.05 1.26 2011 1.22 1.13 1.32
2012 1.12 1.02 1.22 2012 1.32 1.22 1.42
2013 1.11 1.01 1.21 2013 1.45 1.34 1.57
2 1.23   2 104.06 
p-trend 0.2681   p-trend <0.0001 
Socioeconomic deprivation quintile Socioeconomic deprivation quintile
1 (most affluent) 1   1 (most affluent) 1 
2 1.02 0.94 1.11 2 0.97 0.90 1.06
3 0.92 0.84 1.00 3 1.05 0.97 1.13
4 0.88 0.81 0.96 4 1.06 0.98 1.14
5 (most deprived) 0.90 0.83 0.98 5 (most deprived) 1.22 1.13 1.31
2 14.17   2 40.05 
p-trend 0.0002   p-trend <0.0001 
Performance status score Performance status score 
0 1   0 1 
1 0.46 0.43 0.49 1 1.10 1.04 1.17
2 0.16 0.15 0.18 2 0.79 0.73 0.85
3 0.07 0.06 0.09 3 0.24 0.21 0.28
4 0.07 0.04 0.10 4 0.08 0.06 0.12
2 2238.93   2 679.48 
p-trend <0.0001   p-trend <0.0001 
Comorbidity score Comorbidity score
0 1.00   0 1.00 
1 0.97 0.90 1.04 1 1.12 1.05 1.19
2 1.11 1.01 1.22 2 1.02 0.94 1.11
3+ 0.95 0.85 1.06 3+ 1.16 1.05 1.28
2 0.07   2 10.24 
p-trend 0.7872   p-trend 0.0014 
Stage Stage
I 1   I 1 
II 0.52 0.48 0.56 II 0.91 0.83 0.99
III 0.07 0.06 0.07 III 1.02 0.96 1.09
IV 0.01 0.01 0.01 IV 0.13 0.12 0.15
2 13250.56   2 2130.49 
p-trend <0.0001   p-trend <0.0001 
Topography Topography
C33 0.20 0.04 1.02 C33 2.50 1.15 5.44
C340 0.25 0.21 0.29 C340 0.96 0.86 1.07
C341 1     C341 1   
C342 0.94 0.83 1.06 C342 0.81 0.71 0.91
C343 1.22 1.16 1.29 C343 0.70 0.66 0.74
C348 2.91 2.18 3.87 C348 0.36 0.23 0.56
C349 0.30 0.27 0.33 C349 0.80 0.75 0.86
2 108.64   2 26.89 
p-heterogeneity <0.0001   p-heterogeneity <0.0001 
Morphology Morphology
Adenocarcinoma 1   Adenocarcinoma 1 
Carcinoid 1.39 1.21 1.59 Carcinoid 0.32 0.26 0.41
Large cell 1.14 0.93 1.39 Large cell 0.85 0.67 1.08
Non small cell 0.14 0.12 0.15 Non small cell 1.93 1.80 2.08
Other specified 2.88 1.68 4.93 Other specified 0.38 0.19 0.74
Squamous 0.60 0.56 0.63 Squamous 2.05 1.94 2.17
Unspecified 0.06 0.05 0.07 Unspecified 1.13 1.04 1.22
2 530.52   2 163.7 
p-heterogeneity <0.0001   p-heterogeneity <0.0001 
* adjusted for: travel time to nearest thoracic centre, age, sex, 
diagnosis year,  socioeconomic deprivation, performance status, 
comorbidity score, stage, topography and morphology 
  * adjusted for: travel time to nearest radiotherapy centre, age, sex, 
diagnosis year, socioeconomic deprivation, performance status, 
comorbidity score, stage, topography and morphology   
 
 
Supplementary Table B Mortality hazard ratio (95% CI) for surgical resection and radical radiotherapy treatment intensity quintiles from multivariable Cox 
models with imputed data among (a) all NSCLC patients and (b) treated patients only  
a) Surgical resection Radical radiotherapy  b) Surgical resection Radical radiotherapy 
HR 95% CI HR 95% CI  HR 95% CI HR 95% CI 
Model 1: adjusted for age and sex  Model 1: adjusted for age and sex
Q1 ‐ lowest  1.12 1.10 1.13    1.08 1.06 1.10  Q1 ‐ lowest  0.94 0.88 1.00    0.94 0.87 1.02 
Q2  1.06 1.04 1.08    1.04 1.02 1.06  Q2  0.90 0.85 0.96    1.02 0.95 1.10 
Q3  1.04 1.02 1.06    1.06 1.05 1.08  Q3  0.94 0.89 1.00    0.98 0.92 1.04 
Q4  1.02 1.00 1.04    1.02 1.00 1.04  Q4  0.92 0.87 0.98    0.95 0.89 1.01 
Q5 ‐ highest  1      1  Q5 ‐ highest  1    1   
2 172.43   80.74  2 6.13 0.40   
p-trend <0.0001   <0.0001  p-trend 0.0133 0.5265   
Model 2: fully adjusted*  Model 2: fully adjusted*
Q1 ‐ lowest  1.07 1.04 1.09    1.03 1.01 1.05  Q1 ‐ lowest  0.94 0.88 1.01    0.93 0.85 1.01 
Q2  1.02 1.00 1.04    1.05 1.04 1.07  Q2  0.91 0.85 0.97    1.05 0.98 1.13 
Q3  1.04 1.02 1.06    1.05 1.03 1.07  Q3  0.96 0.90 1.02    0.99 0.93 1.06 
Q4  1.00 0.98 1.02    1.01 0.99 1.02  Q4  0.90 0.85 0.95    0.94 0.89 1.00 
Q5 ‐ highest  1      1  Q5 ‐ highest  1    1   
2 46.47   26.53  2 3.03 0.13   
p-trend <0.0001   <0.0001  p-trend 0.0817 0.7232   
* age, sex, diagnosis year, socio-economic deprivation, performance status, 
comorbidity, stage, topography, morphology  
* age, sex, diagnosis year, socio-economic deprivation, performance 
status, comorbidity, stage, topography, morphology 
 



